TheEdgeResearch
Home / Stocks / CCCC

C4 Therapeutics, Inc. (CCCC)

NASDAQ Healthcare Biotechnology
$3.87 ▲ +6.91%
Market Cap
$427.9M
Sector
Healthcare
Industry
Biotechnology
Beta
2.95
52-Wk Range
1.69-5.17
CEO
Andrew J. Hirsch
Country
US
Currency
USD

C4 Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $3.87, up 6.91% on the session, giving a market capitalisation of $427.9M. On trailing twelve-month figures it carries a trailing P/E of -3.87, a net margin of -289.4%. Its beta of 2.95 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.87
Price / Sales
12.21
Price / Book
2.05
EV / EBITDA
-4.13
Gross margin
94.9%
Operating margin
-319.0%
Net margin
-289.4%
Return on equity
Debt / equity
0.23
Current ratio
5.45
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
104
IPO date
2020-10-02
Headquarters
Watertown, MA, US
About C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.

Comparable companies

C4 Therapeutics, Inc. is most often compared with the following Healthcare names:

ARMPCDXSCYBNIMDXMISTMOLNOABIPEPGSAVASGMO
More research on CCCC
CCCC technical analysis CCCC TheEdge Score Compare against peers
Open full interactive analysis & DCF →